Filing Details
- Accession Number:
- 0001209191-11-035210
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-06-17 15:17:34
- Reporting Period:
- 2011-06-15
- Filing Date:
- 2011-06-17
- Accepted Time:
- 2011-06-17 14:17:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
31791 | Perkinelmer Inc | PKI | Laboratory Analytical Instruments (3826) | 042052042 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1224110 | F Robert Friel | 940 Winter Street Waltham MA 02451 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2011-06-15 | 20,000 | $26.05 | 540,922 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on May 10, 2011. Under the plan, Mr. Friel will sell up to an aggregate of 80,000 shares prior to May 11, 2012 and up to an additional 80,000 shares issuable under options to purchase the Issuer's common stock prior to the January 3, 2012 expiration date of such options.
- The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $26.315 to $25.760. The reporting person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The Reporting Person's direct holdings include shares acquired pursuant to the Reporting Person's (i) election to defer stock and/or compensation into the Deferred Compensation Plan, and/or (ii) reinvestment of dividends relating to the Reporting Person's account.